BACE1 and Alzheimer disease: For instance, verubecestat (MK-8931) a potent BACE-1 inhibitor, able to reduce Aβ levels in cerebrospinal fluid up to 81%, was ineffective in AD patients ranging from 55 to 85 years in phase III studies.18